TP53 and cyclic hematopoiesis: To further validate these findings that TP53 mutations or PPM1D mutations themselves are not the cause of increased mutation rate in HSPCs, we studied clone-specific mutation burden analysis using genetically engineered mouse model of therapy-related CH.